CCR2 and metabolic dysfunction-associated steatohepatitis: Surprisingly, CCR2/5 inhibition and PEG-FGF21v treatment resulted in a comparable reduction in hepatic macrophages in experimental NASH, raising the question whether both would act directly on inflammatory cells.